参考文献：
[1] DARZALEX FASPRO™ Prescribing Information, March 2021.
[2] Usmani SZ, et al. J Cancer Re Clin Oncol. 2021 Feb; 147 (2): 619-631
[3] Palladini G, Milani P. Advances in the treatment of light chain amyloidosis. Current Opinion Oncology (2022).
[4] Desport, E., Bridoux, F., Sirac, C. et al. AL Amyloidosis. Orphanet J Rare Dis 7, 54 (2012). https://doi.org/10.1186/1750-1172-7-54
[5] Dispenzieri A., Merlini G. et al. Immunoglobulin Light Chain Systemic Amyloidosis. Cancer Treat Res 169, 273-318 (2016). https://doi.org/10.1007/978-3-319-40320-5_15
[6] Palladini G, et al. Blood. 2020. Epub ahead of print
[7] 原发性轻链型淀粉样变诊断和治疗指南（2021年）
[8] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).Systemic Light Chain Amyloidosis. 2021 Version 2
[9] Mayo Consensus on AL Amyloidosis: Diagnosis, Treatment and Prognosis. 2020
[10] Bumma N, Kahwash R, Parikh SV, Isfort M, Freimer M, Vallakati A, Redder E, Campbell CM, Sharma N, Efebera Y, Stino A. Multidisciplinary amyloidosis care in the era of personalized medicine. Front Neurol. 2022 Oct 13;13:935936. doi: 10.3389/fneur.2022.935936.
[11] Kastritis E, et al. Amyloid. 2021 Mar;28(1):3-11.
[12] Roccatello D, et al, Int J Mol Sci. 2020; 21(11):4129.
[13] 于砚滢，李剑。白血病，淋巴瘤。2021；30（1）：11-13
[14] Kastritis E, et al. ASCO 2021. Abstract 8003.
[15] Raymond L Comenzo, et al. 2021 ASH. Oral 159.
[16] Mateos M-V et al. Efficacy and Safety of the Randomized, Open-Label, Non-inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (pts) With Relapsed or Refractory Multiple Myeloma (RRMM): COLUMBA. 2019 American Society of Clinical Oncology Annual Meeting. June 2019.
[17] Dimopoulos M A et al. Apollo: phase 3 randomized study of subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) versus pomalidomide and dexamethasone (Pd) alone in patients (Pts) with relapsed/refractory multiple myeloma (RRMM)[J]. Blood, 2020, 136: 5-6.
[18] Chari A, Rodriguez‐Otero P, McCarthy H, et al. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study[J]. British Journal of Haematology, 2021, 192(5): 869-878.
